Detalhe da pesquisa
1.
The prevalence of unmet needs in 625 women living beyond a diagnosis of early breast cancer.
Br J Cancer
; 117(8): 1113-1120, 2017 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28859057
2.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 5258, 2022 09 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071033
3.
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.
Oncol Ther
; 8(2): 171-182, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32749634
4.
Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?
Lung Cancer
; 111: 6-11, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838399
5.
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.
Eur J Cancer
; 75: 56-62, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28214659
6.
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nat Commun
; 13(1): 6928, 2022 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36376284
7.
Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Clin Cancer Res
; 21(8): 1869-76, 2015 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25649020
8.
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Invest New Drugs
; 26(1): 67-74, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17805486